What’s new in lipid management for people who have had previous coronary artery bypass graft (CABG) surgery?

Our host, Dr. George Thanassoulis, takes a deeper look into this topic with Dr. Shaun Goodman, a Cardiologist and Associate Head in the Division of Cardiology, Department of Medicine, at St. Michael’s Hospital, and a Professor and Heart & Stroke Foundation of Ontario (Polo) Chair at the University of Toronto’s Department of Medicine. He is Co-Director of the Canadian VIGOUR (Virtual Coordinating Centre for Global Collaborative Cardiovascular Research) Centre.

This episode discusses how the recently updated Canadian Cardiovascular Society Guidelines have changed the clinical practice of lipid management in patients who have had heart bypass surgery. Our experts also touch on common misconceptions associated with such patients and the reasons why this subgroup is at higher risk for future cardiovascular events. They discuss the benefits of more aggressive LDL cholesterol lowering therapies in reducing the risk for future complications in those who had CABG surgery, with a particular focus on PCSK9 inhibitors as demonstrated by evidence from the ODYSSEY OUTCOMES Trial.

Don’t miss the conversation!

The views and opinions expressed in this episode are those of the speakers and do not necessarily reflect the views or positions of any entities they represent.

Declaration of conflict of interest:

Dr.  Thanassoulis:

• Direct financial relationship including receipt of honoraria: Sanofi. Membership on advisory boards or speaker’s bureau: Sanofi, Amgen, Novartis, Silence.

Dr. Goodman:

• Direct financial relationship including receipt of honoraria: Heart and Stroke Foundation of Ontario/University of Toronto (Polo) Chair, Canadian Heart Failure Society, Canadian Heart Research Centre and MD Primer, Canadian VIGOUR Centre, Cleveland Clinic Coordinating Centre for Clinical Research, Duke Clinical Research Institute, New York University Clinical Coordinating Centre, PERFUSE Research Institute, TIMI Study Group (Brigham Health). Membership on advisory boards or speaker’s bureau: Amgen, AstraZeneca, Bayer, Boehringer Ingelheim, Bristol Myers Squibb, CSL Behring, Eli Lilly, Esperion, Ferring Pharmaceuticals, HLS Therapeutics, JAMP Pharma, Merck, Novartis, Pendopharm/Pharmascience, Pfizer, Regeneron, Sanofi, Servier, Tolmar Pharmaceuticals, Valeo Pharma. Funded grants, research or clinical trials: Amgen, Anthos Therapeutics, AstraZeneca, Bayer, Boehringer Ingelheim, Bristol Myers Squibb, CSL Behring, Daiichi-Sankyo/American Regent, Eli Lilly, Esperion, Ferring Pharmaceuticals, Novartis, Novo Nordisk A/C, Pendopharm/Pharmascience, Pfizer, Regeneron, Sanofi.